Pembrolizumab in MarginalzoneLymphoma A MULTICENTER OPEN LABEL SINGLE-ARM PHASE II STUDY
University of Ulm
University of Ulm
Young Adult Survivors United
Scripps Translational Science Institute
Biomea Fusion Inc.
CytomX Therapeutics
CARGO Therapeutics
Celgene
Strata Oncology
Pfizer
Zhejiang DTRM Biopharma
Takeda
Celgene
Taiho Oncology, Inc.
Pfizer
Altor BioScience
Wake Forest University Health Sciences
Centre Hospitalier Henri Duffaut - Avignon
University of Virginia
New Mexico Cancer Research Alliance
Sumitomo Pharma America, Inc.
Hoffmann-La Roche
Asana BioSciences
Seagen Inc.
Bristol-Myers Squibb
AbbVie
AbbVie
Molecular Templates, Inc.
GlaxoSmithKline
miRagen Therapeutics, Inc.
Swiss Cancer Institute
St. Jude Children's Research Hospital
AbbVie
PharmaMar
miRagen Therapeutics, Inc.
Sunesis Pharmaceuticals
University of California, San Diego
Novartis
University of Oklahoma
GlaxoSmithKline
Case Comprehensive Cancer Center
National Institutes of Health Clinical Center (CC)
University of Minnesota
University of California, San Diego
Masonic Cancer Center, University of Minnesota
AHS Cancer Control Alberta
Novartis
Seagen Inc.
Gilead Sciences
Seagen Inc.
Esanex Inc.